volume 2, issue 8, PS361-S362 2007
DOI: 10.1097/01.jto.0000283195.56577.b6
View full text
|
|
Share

Abstract: Background:The Eastern Co-operative Oncology Group (ECOG) 4599 phase III trial demonstrated that the addition of bevacizumab to carboplatin/paclitaxel (CP) significantly improved overall survival and progression-free survival (PFS) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) [Sandler et al., NEJM 2006;355:2542-50]. Cisplatin/gemcitabine (CG) is a combination commonly used in Europe and other regions outside of the USA. In order to establish the efficacy of bevacizumab in combinati…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
4
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals